Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Seres Therapeutics (MCRB) Misses Q2 EPS by 16c
August 3, 2021 7:43 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.53), $0.16 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.26 million versus the consensus estimate of $5.34 million.
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
... More